---

---

tags : Trial    crawled time : 13:01   

save search

---

Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients
Published: 2021-03-11 (Crawled : 13:01) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 253.52% | O: 0.52% H: 0.36% C: -0.63%
RIGL | $1.07 1.91% 1.87% 810K |

Health Technology

| -72.45% | O: 1.28% H: 6.55% C: 6.55%
covid phase 2 trial enroll

---

Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial
Published: 2021-03-05 (Crawled : 13:01) - globenewswire.com
GOSS 4 | $0.7837 -2.77% -2.85% 670K |

Health Technology

| -91.88% | O: 0.31% H: 0.52% C: -1.14%
covid test trial collaboration

---

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-03-02 (Crawled : 13:01) - globenewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K |

Health Technology

| -62.03% | O: 3.48% H: 0.28% C: -4.48%
treatment phase 1 trial phase 3 phase 2 axitinib cls-ax dmd injection

---

TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology
Published: 2021-02-23 (Crawled : 13:01) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M |

Health Technology

| -69.25% | O: -2.81% H: 5.14% C: 2.69%
risk results leukemia phase 3 trial lancet

---

STEYR, New Holland Agriculture, CASE Construction Equipment and FPT Industrial win prestigious 2020 Good Design® Awards
Published: 2021-01-12 (Crawled : 13:01) - globenewswire.com
CNHI | $12.31 -0.73% 0.0% 6.9M |

Producer Manufacturing

| -8.41% | O: 0.3% H: 1.52% C: 1.41%
trial designation awards

---

DLH Wins Renewal of Clinical Support to NIH-Funded AIDS Clinical Trials Group (ACTG)
Published: 2021-01-11 (Crawled : 13:01) - globenewswire.com
DLHC | $11.26 1.99% 1.95% 32K |

Commercial Services

| 13.15% | O: -1.2% H: 0.61% C: -3.46%
trial

---

Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
Published: 2021-01-07 (Crawled : 13:01) - globenewswire.com
TBIO | $0.302 -8.76% -9.6% 160K |

Health Technology

| -98.47% | O: 3.31% H: 3.54% C: 1.96%
results trial fibrosis cystic fibrosis

---

F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
Published: 2021-01-04 (Crawled : 13:01) - globenewswire.com
FSTX | $7.12 0.0% 0 |

Health Technology

| -27.91% | O: 2.94% H: 2.36% C: -9.45%
trial phase 3 phase 1 phase 2

---

Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
Published: 2020-12-17 (Crawled : 13:01) - globenewswire.com
MRUS | $39.83 -1.58% -1.61% 800K |

Health Technology

| 149.28% | O: 0.88% H: 3.35% C: 0.74%
trial phase 3 phase 1 phase 2

---

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial
Published: 2020-12-15 (Crawled : 13:01) - globenewswire.com
PSTV | $1.67 -1.27% -1.28% 25K |

Health Technology

| -19.31% | O: -0.5% H: 1.99% C: -0.5%
trial therapeutics glioblastoma

---

Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M |

Health Technology

| 232.1% | O: -1.62% H: 8.25% C: 6.15%
trial als symposium designation

---

Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Published: 2020-12-14 (Crawled : 13:01) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M |

Health Technology

| -79.39% | O: 55.31% H: 9.73% C: -1.77%
results breast cancer cancer positive endocrine trial trial results phase 2 metastatic breast cancer

---

Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
Published: 2020-12-10 (Crawled : 13:01) - globenewswire.com
SPRO | $1.41 -4.08% -4.26% 380K |

Health Technology

| -91.93% | O: -2.02% H: 1.88% C: 0.18%
disease trial phase 2b

---

Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease
Published: 2020-12-08 (Crawled : 13:01) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -91.81% | O: 1.92% H: 0.94% C: -0.75%
disease alzheimer trial alzheimer’s granted alzheimer's disease alzheimer's

---

Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
Published: 2020-12-03 (Crawled : 13:01) - globenewswire.com
ENLV | $1.4 -4.23% 110K |

Health Technology

| -84.04% | O: 28.9% H: 29.17% C: 6.94%
covid positive results trial

---

Ducommun Announces Participation in Truist Industrials & Services Summit
Published: 2020-12-03 (Crawled : 13:01) - globenewswire.com
DCO | $52.02 0.33% 0.0% 70K |

Electronic Technology

| 1.92% | O: 0.33% H: 2.5% C: 1.84%
trial

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---